Accéder au contenu
Merck
Toutes les photos(2)

Key Documents

SAB4504006

Sigma-Aldrich

Anti-phospho-VEGFR1 (pTyr1333) antibody produced in rabbit

affinity isolated antibody

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(2)

About This Item

Code UNSPSC :
12352203
Nomenclature NACRES :
NA.41

Source biologique

rabbit

Conjugué

unconjugated

Forme d'anticorps

affinity isolated antibody

Type de produit anticorps

primary antibodies

Clone

polyclonal

Forme

buffered aqueous solution

Poids mol.

antigen 150 kDa

Espèces réactives

human, rat, mouse

Concentration

~1 mg/mL

Technique(s)

ELISA: 1:40000
immunohistochemistry: 1:50-1:100
western blot: 1:500-1:1000

Numéro d'accès NCBI

P17948

Numéro d'accès UniProt

P17948

Conditions d'expédition

wet ice

Température de stockage

−20°C

Modification post-traductionnelle de la cible

phosphorylation (pTyr1333)

Informations sur le gène

human ... FLT1(2321)

Description générale

Vascular endothelial growth factor (VEGF) is also known as vascular permeability factor or vasculotropin. It is a 46kDa homodimeric peptide growth factor. This gene is located on human chromosome 13q12.

Immunogène

The antiserum was produced against synthesized peptide derived from human VEGFR1 around the phosphorylation site of Tyr1333.

Immunogen Range: 1289-1338

Application

Anti-phospho-VEGFR1 (pTyr1333) antibody has been used in immunostaining.

Actions biochimiques/physiologiques

Vascular endothelial growth factor (VEGF) activates endothelial cell growth in vitro and angiogenesis in vivo by binding to endothelial cells. This protein participates in endothelial proliferation, regulation of vascular permeability and thrombogenicity.

Caractéristiques et avantages

Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.

Forme physique

Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.

Clause de non-responsabilité

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Vous ne trouvez pas le bon produit ?  

Essayez notre Outil de sélection de produits.

Code de la classe de stockage

10 - Combustible liquids

Classe de danger pour l'eau (WGK)

WGK 1

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Gestational diabetes mellitus is associated with increased pro-migratory activation of vascular endothelial growth factor receptor 2 and reduced expression of vascular endothelial growth factor receptor 1
Troncoso F, et al.
PLoS ONE (2017)
Maryam Farzaneh Behelgardi et al.
Scientific reports, 8(1), 17924-17924 (2018-12-19)
Interfering with interactions of vascular endothelial growth factors (VEGFs) with their receptors (VEGFRs) effectively inhibits angiogenesis and tumor growth. We designed an antagonist peptide of VEGF-A and VEGF-B reproducing two discontinuous receptor binding regions of VEGF-B (loop 1 and loop3)
The genetic differences between gallbladder and bile duct cancer cell lines
Saito S, et al.
Oncology Reports, 16(5), 949-956 (2006)
VEGF165b Modulates Endothelial VEGFR1-STAT3 Signaling Pathway and Angiogenesis in Human and Experimental Peripheral Arterial Disease
Ganta VC, et al.
Circulation Research, 120(2), 282-295 (2017)
Vijay Chaitanya Ganta et al.
Circulation research, 120(2), 282-295 (2016-12-16)
Atherosclerotic-arterial occlusions decrease tissue perfusion causing ischemia to lower limbs in patients with peripheral arterial disease (PAD). Ischemia in muscle induces an angiogenic response, but the magnitude of this response is frequently inadequate to meet tissue perfusion requirements. Alternate splicing

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique